No recent contributors.
Be the first to edit!
| Domain Info
|
|---|
| |
| Map
|
|---|
| |
| AboutUs Badges
|
|---|
 |
Title edit
Boycott Novartis
Description edit
Excerpted from the website:
- About the Campaign
- Novartis, the Swiss Multinational pharmaceutical company, has filed a case in the Chennai High Court against the order of the Chennai Patent office rejecting the patent application filed by them for getting a patent on imatinib mesylate, the trade name being Gleevec. Imatinib mesylate is extremely useful in the treatment of chronic myeloid leukemia (CML). Currently it is being produced in its generic form by NATCO, Cipla, Ranbaxy and Hetero as well as by Novartis under the brand name Gleevec. Treatment with Gleevec, the Novartis’ brand costs Rs. 1.2 lakh (2500 US dollars) per month, whereas the Indian generic versions cost about Rs. 8000 (175 US dollars)! If product patent is granted to Novartis for imatinib mesylate, the Indian generic versions will be forced to go out of the market, while the treatment of the CML would cost Rs. 1.2 lakh per month and this would go out of the reach of 99% of the patients of CML. Novartis price is a clear example of excessive pricing which it has enforced across the world. There is no explanation as to why Novartis is not offering different prices depending on the circumstances in a country like India. It is clear that they are only interested in placing profits before patients lives.
